REACT-SCOT Pharmacoepidemiology (REACT-SCOT-PHARM)

01/06/2020
21/11/2020
EU PAS number:
EUPAS35558
Study
Ongoing
Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Non-interventional study

Non-interventional study design

Case-control
Study drug and medical condition

Medical condition to be studied

COVID-19
Population studied

Age groups

  • Term newborn infants (0 – 27 days)
  • Infants and toddlers (28 days – 23 months)
  • Children (2 to < 12 years)
  • Adolescents (12 to < 18 years)
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

30000
Study design details

Main study objective

A systematic examination of drug exposures and their association with severe COVID-19

Outcomes

Severe COVID -19 defined as entry to critical care unit or death within of a positive nucleic acid test for SARS-CoV-2

Data analysis plan

rate ratios estimated by conditional logistic regression